Tetrahydropyridine LIMK inhibitors: Structure activity studies and biological characterization

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• LIM Kinases (LIMKs), specifically LIMK1 and LIMK2, are key regulators of cytoskeleton remodeling.
• LIMKs are downstream effectors of Rho-GTPase family proteins and regulate cofilin, an actin depolymerizing factor.
• Dysregulation of LIMKs is implicated in several major diseases, making them promising therapeutic targets.

Purpose of the Study:

• To design, synthesize, and biologically evaluate novel tetrahydropyridine pyrrolopyrimidine LIMK inhibitors.
• To understand the binding interactions and structure-activity relationships of these inhibitors.
• To identify potent and selective LIMK inhibitors for potential therapeutic applications.

Main Methods:

• Homology modeling was used to guide compound design and understand binding modes.
• A library of over 60 compounds was synthesized and evaluated for in vitro enzymatic activity.
• In vitro enzymatic assays, cell-based cofilin phosphorylation inhibition assays, kinase selectivity panels, and crystal structure determination were employed.

Main Results:

• Novel tetrahydropyridine pyrrolopyrimidine derivatives were synthesized with in vitro enzymatic activities in the mid to low nanomolar range.
• Compound 52 exhibited excellent selectivity for LIMKs and effectively inhibited cofilin phosphorylation in cells.
• Compound 52 disturbed actin filaments, significantly affected cell cytoskeleton, and reduced cell motility across three cell lines.
• The crystal structure of LIMK2 complexed with compound 52 elucidated key interactions within the active site.

Conclusions:

• The study successfully identified potent and selective LIMK inhibitors, with compound 52 showing significant promise.
• The findings provide a strong foundation for the development of advanced LIMK inhibitors for preclinical validation.
• Understanding the structural basis of inhibition facilitates the design of more effective therapeutic agents targeting LIMK-related diseases.